Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
On April 14, 2022, Mind Medicine (NASDAQ: MNMD) announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti will present results from the LSD-Assist Study, a Phase 2 trial for treating anxiety disorders, at the PSYCH Symposium on May 11, 2022. The study involved 46 patients and aims to evaluate the safety and efficacy of LSD for anxiety management. Preliminary findings indicate the potential benefits of LSD, particularly for patients with severe anxiety linked to life-threatening illness. Positive results may support further development of the company's MM-120 program.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Dr. Francois Lilienthal as Chief Commercial Officer on April 5, 2022. Dr. Lilienthal, with over 20 years of global biopharmaceutical experience, previously consulted for MindMed and will support the company's clinical development programs. CEO Robert Barrow emphasized that Dr. Lilienthal's expertise in global product launches will be vital as MindMed advances its pipeline for brain health disorder treatments. Dr. Lilienthal expressed enthusiasm about joining MindMed at a pivotal time for the neuropsychiatry industry.
MindMed (NASDAQ: MNMD) reported significant developments in its pipeline and financial results for the year ending December 31, 2021. The FDA cleared its IND for the Phase 2b trial of MM-120 to treat generalized anxiety disorder (GAD). As of year-end, the company held $133.5 million in cash, enabling continued operations through key milestones in 2023-2024. However, the net loss increased to $92.3 million, up from $33.7 million in 2020, with R&D expenses rising to $34.8 million. G&A expenses also surged to $59.1 million, largely due to stock-based compensation.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the retirement of Chief Financial Officer David Guebert, effective March 31, 2022. CEO Robert Barrow expressed gratitude for Guebert's contributions to the company's early growth and confirmed that MindMed remains well-positioned financially and strategically. The company has engaged an executive search firm to find a successor with experience in the US biotech market. MindMed is focused on developing innovative treatments for brain health disorders, targeting systems like serotonin, dopamine, and acetylcholine.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will host an earnings call on March 28, 2022, at 8:30 a.m. EDT, to discuss its financial results for the full year ending December 31, 2021, and provide a business update. The call will address the company’s ongoing developments in brain health treatments, particularly focusing on psychiatry and neurology. Participants can join via telephone or access the live webcast through the provided link. This call marks a significant moment for investors seeking insights into MindMed’s performance and future direction.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will participate in several investor conferences this March, showcasing its innovations in treating brain health disorders. Key events include the 34th Annual Roth Conference on March 15, the Oppenheimer Virtual Healthcare Conference on March 17, and the Maxim Virtual Growth Conference from March 28-30. Each event will feature presentations focused on the company's advancements in psychiatry and neurology. A replay of the webcasts will be available on MindMed's website for 30 days post-presentation.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the publication of a study comparing the acute effects of LSD and psilocybin. Published in Neuropsychopharmacology, the study indicates that the differences between both substances are dose-dependent. Key findings suggest that 20 mg psilocybin is equivalent to 100 µg LSD. The research involved 28 participants and highlighted no significant qualitative differences in altered states of consciousness between the two substances, though LSD demonstrated longer effect durations. The study aims to enhance therapeutic potential in treating brain-based disorders.
On February 23, 2022, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a mandatory conversion of its Multiple Voting Shares into Subordinate Voting Shares, effective March 14, 2022. Each Multiple Voting Share will convert to 100 Subordinate Voting Shares. This shift aims to simplify the company's capital structure and emphasizes MindMed's transition to a primarily U.S.-based company. CEO Robert Barrow highlighted that this move benefits both existing and new shareholders. MindMed is focused on developing psychedelic-inspired therapies for brain disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has received FDA clearance for its Phase 2b trial of MM-120, a treatment for generalized anxiety disorder (GAD). This follows the lifting of a clinical hold after MindMed addressed FDA requests regarding participant monitoring. The trial will involve 200 participants and aims to assess anxiety symptom reduction post-administration of MM-120. CEO Robert Barrow highlighted this as a significant milestone, marking the first commercial use of LSD in clinical studies in over 40 years, aiming for improved treatment options for patients with anxiety.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the enrollment of the first subjects in its Session Monitoring System (SMS-01) study, aiming to evaluate sensory data collection during therapy sessions. The FDA provided positive feedback on the development strategy, supporting the study's design. The MSMS aims to enhance psychiatric care through innovative data analysis. MindMed focuses on psychedelic-inspired therapies for mental health and addiction, leveraging collaborations in its development pipeline.
